January 27, 2021
2 min read
Association of Community Cancer Centers presented awards to three oncologists for their contributions to cancer treatment, clinical research and reducing disparities.
Roy S. Herbst, MD, PhD, received the Clinical Research Award. The award is presented to individuals whose research significantly and positively impacted people with cancer, their families and caregivers, and communities.
Roy S. Herbst
Herbst is Ensign professor of medicine, professor of pharmacology, chief of medical oncology and associate director for translational research at Yale Cancer Center and Smilow Cancer Hospital.
The award recognizes his distinguished career in lung cancer research, as well as his efforts that helped pioneer immunotherapy and personalized medicine.
“Dr. Herbst was selected for this award based on his distinguished and effective accomplishments in lung cancer research, having successfully integrated biology and laboratory research, team-based science, broad collaboration, and community, patient, public and private partnerships that have served as a roadmap and role model for others,” Randall A. Oyer, MD, ACCC president and medical director of the oncology program at Penn Medicine Lancaster General Health, said in a press release. “The work of Dr. Herbst and his team has importantly led to the approval of several treatments that have revolutionized lung cancer care, improved patient survival and changed patient expectations.”
Worta McCaskill-Stevens, MD, MS, received the David King Community Clinical Science Award. The award is presented to active community clinical research leaders who demonstrated leadership in the development, participation and evaluation of clinical studies, and who are active in the development of new screening, risk assessment, treatment or supportive care programs for people with cancer.
McCaskill-Stevens is medical oncologist and chief of the community oncology and prevention trials research group, which houses the NCI community oncology research program.
Her work has focused on cancer disparities, management of comorbidities within clinical trials, and molecular research to determine which individuals might derive the greatest benefit from cancer prevention interventions.
She also has conducted extensive breast cancer research and played an important role in ensuring the advancement of minority investigators in cancer research.
“Dr. McCaskill-Stevens’ effective leadership has created community and academic partnerships, expanded types and numbers of trials available in communities across the United States, [and] incorporated disparities research and biobanking to advance precision medicine,” Oyer said. “Patients will forever benefit from her work.”
Lawrence N. Shulman, MD, MACP, FASCO, received the Annual Achievement Award. The award recognizes distinguished individuals or organizations that reflect the values of community cancer care through their outstanding contributions.
Lawrence N. Shulman
Shulman is professor of medicine at Perelman School of Medicine, deputy director for clinical services and director of Center for Global Cancer Medicine at Abramson Cancer Center at University of Pennsylvania.
The award recognizes Shulman for his work as a breast oncologist, teacher and mentor, as well as for his work in low-resourced areas of the United States and around the world, through which he has promoted early detection and the establishment of cancer treatment programs.
“I have the pleasure of working with Dr. Shulman at the University of Pennsylvania and, therefore, have a chance to personally witness his leadership and passion for the oncology community setting,” Oyer said. “What he’s achieved through his work in countries like Rwanda, Haiti and Botswana is remarkable.
“For example, Dr. Shulman and his colleagues trained hundreds of clinicians in breast health care and provided breast exam screening to thousands of patients in four districts of Rwanda,” Oyer added. “Their efforts have led to a significant improvement in patient outcomes in an area where women have a much higher risk of dying of breast cancer.”